In the GEPIA2 database, high MIDN expression was linked with shortened disease-free survival (DFS) in patients with uveal melanoma (UVM) and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), as well as with prolonged DFS in patients of esophageal carcinoma (ESCA, Figure 3A–D). This evidence concerns the gene MIDN and uveal melanoma.